AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 101 min read$FTRE

Morais Mark A. sold $53K of FTRE

Morais Mark A. (Chief Operating Officer) sold 3,149 shares of Fortrea Holdings Inc. (FTRE) at $16.85 on 2026-09-09.

Original reporting
SEC EDGAR · Morais Mark A.
Published Sep 10, 2026, 8:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 10, 2026, 8:38 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$FTRE
Neutral
high confidence
Mentioned
$FTRE
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$FTRENeutralLow
01

Why it matters

The disclosed sale is the first public report of this transaction, but its modest size limits market impact.

02

Market read

A routine insider sell with minimal trading relevance.

03

What to watch

Potential upcoming corporate actions or financing needs not disclosed.

Relevance 3/10Novelty 4/10Timing: post‑market Sep 9 2026

Background

Form 4 filing from SEC EDGAR reporting an insider sale by Fortrea's COO.

Company-level read

Ticker impact

$FTRENeutralHigh confidence
Context

COO Morais Mark A. sold 3,149 shares for $53,060.65 on Sep 9, reducing his stake to 81,794 shares.

Expected impact

Minimal downward pressure, unlikely to move price materially.

Evidence & confidence

The transaction amount is under $100k and represents a tiny fraction of total shares outstanding.

Market effects

Sector

None; Fortrea operates in a niche sector with limited peer impact.

Regional

No broader regional effect.

Global

Insignificant.

Counterpoint

What could challenge this read

The sell could be a routine portfolio rebalancing, not a red flag.

Key entities

  • Company
    Fortrea Holdings Inc.

    US‑listed biotech firm (ticker FTRE).

  • Insider
    Morais Mark A.

    Chief Operating Officer of Fortrea.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

FTRE insider trading history →

Related articles

SEP 2
$FTREMed

Fortrea (FTRE) Stock Is Up, What You Need To Know

Fortrea Holdings (FTRE) shares rose 2.8% after acquiring Worldwide Clinical Trials' Early Phase Services division, expanding its clinical research capabilities. The acquisition includes facilities in Texas. Fortrea's stock is volatile, with a 52-week high of $20.70. Q3 revenue was $701.3M, beating estimates, but earnings missed. Full-year revenue guidance was raised to $2.73B.

financialcontent.com2 min
SEP 2
$FTREHigh

Fortrea To Acquire Early Phase Services From Worldwide Clinical Trials; Stock Up

Fortrea Holdings (FTRE) agreed to buy the Early Phase Services division of Worldwide Clinical Trials, including labs and clinical units in Texas. The deal expands Fortrea's early development network, adding bioanalytical and clinical pharmacology capabilities. FTRE shares rose 5.98% to $18.78. According to the company, the acquisition supports growth and increases long-term shareholder value.

rttnews.com2 min
SEP 2
$FTREMed

Fortrea Holdings Inc: Fortrea to Acquire Clinical Pharmacology Unit and Bioanalytical Laboratory Operations from Worldwide Clinical Trials

Fortrea (FTRE) will acquire Worldwide Clinical Trials' Early Phase Services division for $45M, including a bioanalytical lab and clinical pharmacology unit. The deal expands Fortrea's early clinical development capabilities, enhancing its platform for Phases I-IV studies. Worldwide will focus on its late-stage business. The transaction is subject to regulatory approvals.

finanznachrichten.de2 min